Eli Lilly (LLY)
883.96
-33.69 (-3.67%)
NYSE · Last Trade: Apr 24th, 6:02 PM EDT
Detailed Quote
| Previous Close | 917.65 |
|---|---|
| Open | 900.01 |
| Bid | 883.65 |
| Ask | 884.00 |
| Day's Range | 871.73 - 900.42 |
| 52 Week Range | 623.78 - 1,133.95 |
| Volume | 4,457,979 |
| Market Cap | 845.58B |
| PE Ratio (TTM) | 38.52 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.78%) |
| 1 Month Average Volume | 2,794,548 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.6% in the afternoon session after disappointing weekly prescription number...
Via StockStory · April 24, 2026
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Via Chartmill · April 24, 2026
Major M&A deals this week include Eli Lilly buys Kelonia for $7 billion, Honeywell sells PSS to Brady Corp., KSL buys Invited Clubs.
Via Benzinga · April 24, 2026
These S&P500 stocks are gapping in today's sessionchartmill.com
Via Chartmill · April 24, 2026
Indianapolis, IN - CX Research Institute announced today the publication of its comprehensive research report evaluating the best expert matchmakers in the Indianapolis metropolitan area. VIDA Select earned the top ranking with a score of 92 out of 100 points, leading eight other prominent matchmaking and dating services in a rigorous comparative analysis.
Via AB Newswire · April 24, 2026
Eli Lilly stock skidded early Friday as Novo Nordisk's oral Wegovy continued to outpace Lilly's new obesity pill, Foundayo.
Via Investor's Business Daily · April 24, 2026
Young adults with median earnings can build sizable portfolios by retirement by regularly purchasing shares of the Vanguard S&P 500 Growth ETF.
Via The Motley Fool · April 24, 2026
Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking...
Via StockStory · April 23, 2026
Federated Hermes delivers asset management solutions across equity, fixed income, and money market funds to a diverse client base.
Via The Motley Fool · April 23, 2026
Amazon is expanding into integrated weight-loss care with a scalable healthcare model. Can this expansion meaningfully drive AMZN stock upside?
Via Barchart.com · April 23, 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The CRDL lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
Via Get News · April 23, 2026
Novo Nordisk stock has been stuck in a downward spiral for quite some time.
Via The Motley Fool · April 23, 2026
Hims & Hers Health can now connect its customers with self-pay prices for Eli Lilly's weight-loss drugs.
Via Investor's Business Daily · April 23, 2026
Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.
Via The Motley Fool · April 23, 2026
From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met
By Equity Insider · Via GlobeNewswire · April 23, 2026
These companies offer a clear path to sustained earnings growth.
Via The Motley Fool · April 23, 2026
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Elanco (NYSE:ELAN) and its peers. The pharmaceuti...
Via StockStory · April 22, 2026
Eli Lilly stock trades for more than $900 per share, which may appear expensive upon first glance.
Via The Motley Fool · April 22, 2026
What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a...
Via StockStory · April 21, 2026
Can Eli Lilly cure cancer? Maybe -- with a little help.
Via The Motley Fool · April 21, 2026
Shares of Eli Lilly, Novo Nordisk and Viking Therapeutics fell Tuesday after Amazon announced it would sell weight-loss drugs.
Via Investor's Business Daily · April 21, 2026
Which S&P500 stocks are gapping on Tuesday?chartmill.com
Via Chartmill · April 21, 2026
There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.
Via The Motley Fool · April 21, 2026
After Fifteen Years, Tim Cook Steps Down, Wall Street Steps Back, Oil Steps Upchartmill.com
Via Chartmill · April 21, 2026
Two analysts weighed in positively about the company's future.
Via The Motley Fool · April 20, 2026
